The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...

David Lieberman, MD, PhD, reviews the potential role and the goals of gene therapy in the treatment of Rett syndrome. The goals of therapy, as I see it for Rett syndrome, should be treating the ...

An expert discusses the current treatment landscape of Rett syndrome including the goals of treatment and implications for utilization management strategies with the disease. David Lieberman, MD, PhD: ...

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program ...

Recently, Taysha Gene Therapies announced it has regained full rights to its lead gene therapy candidate TSHA-102 for Rett syndrome after the expiration of an option agreement with Astellas, following ...

Please provide your email address to receive an email when new articles are posted on . Health Canada has authorized an amendment to the ongoing REVEAL phase 1/2 trial evaluating an AAV9 ...

In a comprehensive preclinical program, NGN-401 demonstrated robust therapeutic and safety benefits, delivering MECP2 to key brain regions affected by Rett syndrome NGN-401 utilizes Neurogene’s ...

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for ...

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc.

Credit: Acadia Pharmaceuticals. The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study. The Food and Drug Administration (FDA) has approved ...

Credit: Getty Images. TSHA-102 is an investigational adeno-associated virus 9 gene transfer therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to TSHA-102 for the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted regenerative medicine advanced therapy designation to an intrathecally delivered AAV9 gene ...